Puma Biotechnology(PBYI)

Focus: Puma Biotechnology is a Los Angeles-based oncology-focused biotech company founded in 2010, publicly traded (NASDAQ: PBYI) with a single commercial product driving all revenue. The company specializes in the acquisition and development of targeted cancer therapies.

Oncology

Profile data last refreshed 13m ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

10+2 this month

Stable — net +2 jobs in 30d

6 added, 4 removed. Backfill posture.

Should You Work at Puma Biotechnology?

AI assessment

Puma is a stable, profitable, single-asset oncology company suitable for professionals seeking immediate impact in commercialization or clinical development, but unsuitable for those prioritizing long-term career security or deep scientific learning.

Why Work Here

NERLYNX is at peak lifecycle with $37M in Part D spending and patent protection through 2031, providing near-term revenue stability and oncology credibility.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

50 total

LOE Risk

1 in 5yr

NERLYNX

Hiring

Stable

Revenue

$236M

FY2025

Key Products

NERLYNX

Multiple oncology indications including HER2-positive breast cancer, HER2-mutant solid tumors, and EGFR-expressing carcinomas

$37M Part D

Peak

Help build intelligence for Puma Biotechnology

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Pipeline & Clinical Trials

Neratinib

Healthy

N/A

Clinical Trials (1)

NCT01142063A Single Dose Bioequivalence Study Of Neratinib In Healthy Subjects

N/A

Almac HER-Seq Assay

Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

N/A

Clinical Trials (1)

NCT03786107HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib

N/A

Neratinib

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT00864487Study Evaluating The Potential Effect Of Rifampin On The Pharmacokinetics Of Neratinib

Phase 1

neratinib

Healthy

Phase 1

Clinical Trials (1)

NCT00550212Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects

Phase 1

neratinib

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT00814060Study Evaluating TwoTablet Formulations of Neratinib (HKI-272)

Phase 1

Neratinib

Neoplasms

Phase 1

Clinical Trials (1)

NCT00838539Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Phase 1

Digoxin

Healthy

Phase 1

Clinical Trials (1)

NCT00860223Study Evaluating The Potential Effect Of Multiple Doses Of Neratinib On The Pharmacokinetics Of A Single Dose Of Digoxin

Phase 1

Neratinib Pill

Gastric Cancer

Phase 1

Clinical Trials (1)

NCT05274048Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients

Phase 1

neratinib

Healthy

Phase 1

Clinical Trials (1)

NCT00366600Study Evaluating HKI-272 Administered to Healthy Subjects

Phase 1

neratinib

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT00757809Study Evaluating The Tolerability Of Multiple Doses Of HKI-272

Phase 1

Osimertinib

Lung Cancer Metastatic

Phase 1

Clinical Trials (1)

NCT04085315Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

Phase 1

Neratinib

Healthy

Phase 1

Clinical Trials (1)

NCT00932464Study Evaluating The Effect Of A High-Fat Meal On The Pharmacokinetics Of Neratinib

Phase 1

Lansoprazole

Healthy

Phase 1

Clinical Trials (1)

NCT02334501Open-label PK Study to Evaluate Lansoprazole and Neratinib in Healthy Subjects

Phase 1

neratinib

Breast Neoplasms

Phase 1

Clinical Trials (1)

NCT00146172Study Evaluating HKI-272 in Tumors

Phase 1

neratinib

Tumors

Phase 1

Clinical Trials (1)

NCT00397046A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors

Phase 1

neratinib

Healthy

Phase 1

Clinical Trials (1)

NCT00380328HKI-272 Ketoconazole Drug Interaction Study

Phase 1

neratinib

Breast Cancer

Phase 1

Clinical Trials (1)

NCT00708903Study to Examine the Effect of HKI-272 on Rhythms of the Heart (Cardiac Repolarization)

Phase 1

Neratinib

Hepatic Insufficiency

Phase 1

Clinical Trials (1)

NCT00781430Study Evaluating The PK And Safety Of Neratinib In Healthy Subjects And Subjects With Chronic Liver Disease

Phase 1

neratinib

Healthy

Phase 1

Clinical Trials (1)

NCT00498745Study Comparing 2 New Formulations of HKI-272 in Healthy Adult Subjects

Phase 1

Neratinib 160 mg

Advanced Solid Tumor

Phase 1

Clinical Trials (1)

NCT04502602Niraparib and Neratinib in Advanced Solid Tumors With Expansion Cohort in Advanced Ovarian Cancer

Phase 1

Neratinib

Advanced Malignant Solid Tumors

Phase 1

Clinical Trials (1)

NCT00958724Study Evaluating Neratinib In Combination With Vinorelbine In Subjects With Advanced Or Metastatic Solid Tumors

Phase 1

Neratinib

Advanced Malignant Solid Tumors

Phase 1

Clinical Trials (1)

NCT01128842A Study Of Neratinib (HKI-272) And Capecitabine In Japanese With Solid Tumor

Phase 1

Neratinib

Advanced Malignant Solid Tumors

Phase 1

Clinical Trials (1)

NCT00768469Study Evaluating Safety And Tolerability, Solid Tumor

Phase 1

HKI-272

Advanced Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT00445458A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Phase 1/2

Neratinib

Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT00741260Study Evaluating The Combination Of Neratinib And Capecitabine In Solid Tumors And Breast Cancer

Phase 1/2

HKI-272

Advanced Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT00398567A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

Phase 1/2

Neratinib

Solid Tumor, Adult

Phase 1/2

Clinical Trials (1)

NCT03919292Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca

Phase 1/2

neratinib

Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT00706030Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer

Phase 1/2

Temsirolimus

Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT01111825Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer

Phase 1/2

Neratinib

Metastatic Breast Cancer

Phase 1/2

Neratinib

Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT02236000A Dose-Escalation Study Evaluating the Combination of Trastuzumab Emtansine (T-DM1) With Neratinib in Women With Metastatic HER2-Positive Breast Cancer

Phase 1/2

Capecitabine

Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT03377387Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer

Phase 1/2

Neratinib

Breast Cancer

Phase 2

Clinical Trials (1)

NCT03289039Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

Phase 2

Neratinib

Metastatic Prostate Adenocarcinoma

Phase 2

Clinical Trials (1)

NCT04781374Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2

Neratinib

Triple Negative Breast Cancer

Phase 2

Clinical Trials (1)

NCT03812393Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast

Phase 2

Paclitaxel

Breast Cancer

Phase 2

Clinical Trials (1)

NCT01008150Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

Phase 2

Alisertib

Hormone Receptor Positive HER-2 Negative Breast Cancer

Phase 2

Clinical Trials (1)

NCT06369285A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Phase 2

Neratinib

Breast Cancer

Phase 2

Clinical Trials (1)

NCT04886531Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

Phase 2

HKI-272

Breast Cancer

Phase 2

Clinical Trials (1)

NCT01494662HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

Phase 2

Neratinib

HER2-positive Breast Cancer

Phase 2

Clinical Trials (1)

NCT03094052Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

Phase 2

neratinib

Breast Neoplasms

Phase 2

Clinical Trials (1)

NCT00300781Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Phase 2

NERATINIB

Stage IV (Metastatic) Breast Cancer

Phase 2

Clinical Trials (1)

NCT04901299Fulvestrant + Neratinib In Breast Cancer

Phase 2

Neratinib

Breast Cancer

Phase 2

Clinical Trials (1)

NCT00915018Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer

Phase 2

Neratinib

HER2 Amplified Breast Cancer

Phase 2

Clinical Trials (1)

NCT04366713A Study to Characterize Colon Pathology in Patients With HER2 Amplified Breast Cancer Treated With Neratinib

Phase 2

Temozolomide

Glioblastoma

Phase 2

Neratinib

Early Stage HER2+ Breast Cancer

Phase 2

Clinical Trials (1)

NCT02400476An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

Phase 2

neratinib

HER2-mutant Non-Small Cell Lung Cancer

Phase 2

Clinical Trials (1)

NCT01827267Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

Phase 2

Neratinib

Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Phase 2

Clinical Trials (1)

NCT01953926Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Phase 2

Alisertib

Small Cell Lung Cancer

Phase 2

Clinical Trials (1)

NCT06095505A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer

Phase 2

Neratinib

Advanced Breast Cancer

Phase 2

Clinical Trials (1)

NCT00777101Study Evaluating Neratinib Versus Lapatinib Plus Capecitabine For ErbB2 Positive Advanced Breast Cancer

Phase 2

Puma Biotechnology(PBYI)

Should You Work at Puma Biotechnology?

Why Work Here

Key Products

Watch Out For

Products & Portfolio (1)

Key Products by Revenue

Pipeline & Clinical Trials

Open Jobs (10)

Senior Oncology Sales Specialist

Senior Oncology Sales Specialist

Senior Oncology Sales Specialist

Financials (FY2025)

Hiring Trend

Private Funding (SEC Form D)